Canada Approves 2 Drugs for Bone Health in Cancer Patients

Patients struggling with bone loss now have two new affordable treatment options, thanks to Health Canada's approval of biosimilar drugs Bosaya and Vevzuo on April 3, 2026.

The medications treat osteoporosis and bone complications that often plague cancer patients. Biocon Ltd, the company behind the drugs, specializes in creating biosimilars, which are high-quality alternatives to expensive brand-name biologic medicines.

Both drugs contain denosumab, a proven ingredient that strengthens bones and prevents fractures. For cancer patients dealing with tumors that spread to bones, these complications can be devastating and painful.

CEO Shreehas Tambe says the approval reflects Biocon's mission to make critical treatments accessible without sacrificing quality or effectiveness. The company already offers biosimilars across immunology and oncology, helping patients worldwide afford medications that were once out of reach.

Osteoporosis affects millions of people, especially older women, causing bones to become brittle and break easily. Cancer patients face additional bone risks from both the disease and certain treatments, making prevention crucial for maintaining quality of life.

The Ripple Effect

This approval extends far beyond just two new drug names on pharmacy shelves. Biosimilars typically cost 30 to 50 percent less than original biologic drugs, freeing up healthcare dollars that can serve more patients.

When one country approves a biosimilar, it often creates momentum for approvals elsewhere. Canada's decision could encourage other nations to fast-track similar affordable options, benefiting patients globally who struggle to pay for bone-protecting medications.

The move also validates biosimilars as safe, effective alternatives in the eyes of one of the world's most rigorous regulatory agencies. That vote of confidence helps doctors and patients feel comfortable choosing these cost-saving options.

For Biocon, the Canadian market represents another step in making affordable biologics available worldwide. The New Delhi-based company continues expanding its global footprint, bringing down costs in markets from North America to Europe.

Patients in Canada can expect these medications to reach pharmacies in the coming months, offering new hope for those who previously couldn't afford treatment or struggled with limited options for protecting their bone health during cancer treatment.